Chronic hepatitis delta is chronic liver inflammation caused by hepatitis D virus (HDV) in people with chronic hepatitis B infection, because HDV requires HBV for replication. It is considered the most severe form of chronic viral hepatitis, with faster progression to cirrhosis, liver failure, and hepatocellular carcinoma.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07096193 |
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus |
RECRUITING | PHASE1/PHASE2 |
| NCT05953545 |
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis |
WITHDRAWN | PHASE2 |
| NCT04170452 |
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta |
UNKNOWN | |
| NCT03852719 |
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) |
COMPLETED | PHASE3 |
| NCT03852433 |
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) |
COMPLETED | PHASE2 |
